peptide drug conjugate fda approved Mylotarg (gemtuzumab ozogamicin) became the first ADC approved by the FDA - Peptideconjugation Food and Drug Administration (FDA)-approved antibody-drug conjugates

Peptideconjugation

FDA-Approved Peptide Drug Conjugates: A Growing Frontier in Targeted Therapy

The landscape of targeted therapeutics has been significantly advanced by the development of peptide drug conjugates (PDCs), a class of drugs designed to deliver potent payloads directly to specific cells.作者：D Wang·2025·被引用次数：29—Since the first ADC drug,mylotarg (gemtuzumab ozogamicin), was approved by the Food and Drug Administration (FDA) in 2000 for adults with acute ... The FDA-approved peptide drug conjugate landscape is rapidly evolving, offering new hope for treating various diseases, most notably cancer. These sophisticated molecules combine the targeting precision of peptides with the efficacy of cytotoxic drugs, minimizing systemic toxicity and maximizing therapeutic impact.2025年2月19日—Peptide drug conjugates(PDCs) represent a groundbreaking approach in targeted therapy, offering a powerful strategy for treating diseases, particularly cancer.

Currently, the number of FDA-approved PDCs is relatively small but growing, with key examples paving the way for future innovationspeptide-drug-conjugates-pdcs-novel-targeted-therapeutics .... Understanding these approved agents is crucial for appreciating the potential and current status of this therapeutic modality.

#### Key FDA-Approved Peptide Drug Conjugates

The journey of FDA-approved PDCs has seen the emergence of several critical agents, primarily in the realm of oncology.2025年3月17日—A careful review of the available data reveals thatat least six distinct FDA-approved peptide conjugate radionuclideshave been reported. These ...

* Lutathera (177Lu-dotatate or 177Lu-DOTA-TATE): This radiolabeled peptide is a landmark therapy.作者：G Jia·2024·被引用次数：26—Food and Drug Administration (FDA)-approved antibody-drug conjugates(ADCs) have shown good efficacy in treating various cancers; however, they still ... Approved by the FDA, Lutathera targets somatostatin receptors, which are often overexpressed on neuroendocrine tumors. The attached radioactive isotope, Lutetium-177, delivers targeted radiation directly to cancer cells expressing these receptors, making it a crucial treatment for certain gastrointestinal and pancreatic neuroendocrine tumorsCurrently, two PDC drugs (Figure 1) are approved for marketing by the U.S. Food and Drug Administration (FDA).177Lu-DOTA-TATE (Lutathera) was approved in 2018 .... Novartis developed this pioneering drug, which was among the first PDCs to receive FDA approvalAntibody-drug conjugates (ADCs) have had significant ....

* Pepaxto (Melflufen): Another significant FDA-approved PDC is Pepaxto, also known as melflufen作者：M Wang·2024·被引用次数：74—Two PDCs have been approved by the US Food and Drug Administration (FDA) for the treatment of cancer. The therapeutic effects of PDCs are .... This drug is a peptide-drug conjugate designed to target cancer cells. It was approved for specific hematological malignancies, demonstrating the versatility of PDCs beyond solid tumorsPeptide Drug Conjugates: A New Frontier in Targeted .... However, it's important to note that regulatory statuses can evolve, and some approvals, like that for Pepaxto in certain contexts, have seen complexities or withdrawals in different regions, underscoring the dynamic nature of drug approvalPeptide Drug Conjugates Market.

* 68Ga PSMA-11: While primarily a diagnostic reagent for PET imaging in men with prostate cancer, 68Ga PSMA-11 represents an important FDA-approved peptide conjugate.Peptide–drug conjugates (PDCs): a novel trend of ... - PMC - NIH Its approval highlights the utility of peptide conjugates not only for therapy but also for precise disease detection, which is a critical component of personalized cancer care.

It is worth noting that there can be variations in how PDCs are categorized, and some sources may list different numbers or types of approvals depending on the specific criteria used (e.g., including diagnostic agents, or distinguishing between therapeutic and diagnostic radiopharmaceuticals).2025年7月11日—Although theFDAhas withdrawn approval for Pepaxto, the EMA and the UK's MHRA haveapprovedit under the brand name Pepaxti for use in ... However, Lutathera and Pepaxto are consistently cited as key therapeutic PDCs.FDA Clears Peptide-Drug Conjugate for RRMM

#### The Mechanism and Promise of Peptide Drug Conjugates

Peptide drug conjugates operate on a principle of targeted delivery.How many FDA approved Peptide drug conjugates are ... A peptide, which is a short chain of amino acids, is carefully selected for its ability to bind to specific receptors or antigens that are highly expressed on the surface of diseased cells, such as cancer cellsFDA Approved Anticancer Peptide Drug Conjugate Market .... This peptide acts as a homing device作者：K Jadhav·2025·被引用次数：21—A notable example is theFDA-approved radionuclide-containing PDC, In-DTPA-Octreotide (Octreoscan), used for diagnosing neuroendocrine tumors. However, .... Attached to the peptide, via a linker molecule, is a potent therapeutic payload. This payload is often a cytotoxic drug, capable of killing cells, or in the case of radiolabeled PDCs, a radioactive isotope that induces cell death through radiation.

When the PDC encounters a cell expressing the target receptor, the peptide binds to it, facilitating the internalization of the entire conjugate into the cell. Once inside, the linker is cleaved, releasing the cytotoxic payload or activating the radioactive isotope.Peptide–Drug Conjugates as Next-Generation Therapeutics This localized release ensures that the toxic effects are concentrated within the targeted cells, thereby sparing healthy tissues and reducing the debilitating side effects often associated with conventional chemotherapy.

The advantage of using peptides over larger molecules like antibodies (as in Antibody-Drug Conjugates or ADCs) lies in their smaller size. This allows PDCs to potentially penetrate solid tumors more effectively and be cleared from circulation more rapidly, which can be beneficial for drug delivery and reducing off-target toxicities.

#### Future Directions and Research Advances

The success of currently approved peptide drug conjugates has spurred significant research and development efforts. Scientists are exploring novel peptides that can target a wider range of cancers and other diseases, as well as developing more sophisticated linker technologies and potent payloads. The field is also looking at combining PDCs with other therapeutic modalities, such as immunotherapy, to achieve synergistic effects2025年6月5日—As of May 2025,2 peptide drug conjugates have been approvedby the regulators. Novartis's Lutathera, a radiolabeled peptide for the treatment ....

The development of PDCs represents a significant step forward in precision medicine. As our understanding of disease biology deepens and our capabilities in molecular engineering advance, we can anticipate an expanding pipeline of FDA-approved peptide drug conjugates, offering more effective and less toxic treatment options for patients facing serious illnesses. The journey from research bench to FDA approval is complex, but the growing list of approved agents signifies a promising future for this innovative class of therapeutics.How many FDA approved Peptide Conjugate Radionuclide ...